Education
About Us
Working with TipRanks
Follow Us
Hims & Hers Health (HIMS)
NYSE:HIMS
HIMS Analyst Ratings
Hold
2 Buy
7 Hold
2 Sell
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months
HIMS Stock 12 Month Forecast
Average Price Target
$49.11
▲(1.61% Upside)
| Highest Price Target$85.00 | Average Price Target$49.11 | Lowest Price Target$28.00 |
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.
Detailed List of Analyst Forecasts
Detailed List of Analyst Forecasts
Canaccord Genuity
$68
Buy
40.70%
Upside
Reiterated
08/13/25
Strategic Investments and Market Opportunities Drive Buy Rating for Hims & Hers HealthWe hosted a fireside chat with Hims & Hers' CFO Growth Conference. Key discussion topics included expanding personalization capabilities, new treatments, trends in the weight loss segment, how AI is impacting the platform, international expansion efforts, and dynamics impacting core growth.
Morgan Stanley
$40
Hold
-17.24%
Downside
Reiterated
08/13/25
TR | OpenAI - 4o
$72→$52
Hold
7.59%
Upside
Downgraded
08/13/25
Deutsche Bank
$43→$48
Hold
-0.68%
Downside
Reiterated
08/06/25
Bank of America Securities
$28
Sell
-42.06%
Downside
Reiterated
08/06/25
Leerink Partners
$42→$43
Hold
-11.03%
Downside
Reiterated
08/06/25
Needham
―
Hold
―
Reiterated
08/05/25
TD Cowen
$43→$48
Hold
-0.68%
Downside
Reiterated
08/05/25
Hold Rating for Hims & Hers Health Amid Mixed Results and Growth InvestmentsWe believe HIMS is building the right infrastructure for future growth by investing behind new specialties, lab testing capabilities, and technology, while simultaneously targeting international expansion. That said, to achieve these long-term goals, we expect HIMS to invest in the business over the next year, which will likely weigh on margins. Further, there are near-term headwinds, such as the impact of transitioning subscribers to daily offerings within sexual health and tougher comparisons in 2H25 that may limit substantial upside in FY25 vs. elevated expectations for the stock. We remain Hold given the near-term dynamics but raise our PT to $48 based on ~4x FY2 EV/Sales.
BTIG
$85
Buy
75.87%
Upside
Reiterated
08/05/25
Truist Financial
―
Hold
―
Reiterated
08/05/25
Citi
$30
Sell
-37.93%
Downside
Reiterated
07/09/25
Piper Sandler
$35→$39
Hold
-19.30%
Downside
Reiterated
05/06/25
Jefferies
$21→$25
Hold
-48.27%
Downside
Reiterated
04/11/25
Barclays
$40
Hold
-17.24%
Downside
Downgraded
02/25/25
Ranks
Any
Analyst Rating
Any
Upside/ Downside
Any
Action
Any
Canaccord Genuity
$68
Buy
40.70%
Upside
Reiterated
08/13/25
Strategic Investments and Market Opportunities Drive Buy Rating for Hims & Hers HealthWe hosted a fireside chat with Hims & Hers' CFO Growth Conference. Key discussion topics included expanding personalization capabilities, new treatments, trends in the weight loss segment, how AI is impacting the platform, international expansion efforts, and dynamics impacting core growth.
Morgan Stanley
$40
Hold
-17.24%
Downside
Reiterated
08/13/25
TR | OpenAI - 4o
$72→$52
Hold
7.59%
Upside
Downgraded
08/13/25
Deutsche Bank
$43→$48
Hold
-0.68%
Downside
Reiterated
08/06/25
Bank of America Securities
$28
Sell
-42.06%
Downside
Reiterated
08/06/25
Leerink Partners
$42→$43
Hold
-11.03%
Downside
Reiterated
08/06/25
Needham
―
Hold
―
Reiterated
08/05/25
TD Cowen
$43→$48
Hold
-0.68%
Downside
Reiterated
08/05/25
Hold Rating for Hims & Hers Health Amid Mixed Results and Growth InvestmentsWe believe HIMS is building the right infrastructure for future growth by investing behind new specialties, lab testing capabilities, and technology, while simultaneously targeting international expansion. That said, to achieve these long-term goals, we expect HIMS to invest in the business over the next year, which will likely weigh on margins. Further, there are near-term headwinds, such as the impact of transitioning subscribers to daily offerings within sexual health and tougher comparisons in 2H25 that may limit substantial upside in FY25 vs. elevated expectations for the stock. We remain Hold given the near-term dynamics but raise our PT to $48 based on ~4x FY2 EV/Sales.
BTIG
$85
Buy
75.87%
Upside
Reiterated
08/05/25
Truist Financial
―
Hold
―
Reiterated
08/05/25
Citi
$30
Sell
-37.93%
Downside
Reiterated
07/09/25
Piper Sandler
$35→$39
Hold
-19.30%
Downside
Reiterated
05/06/25
Jefferies
$21→$25
Hold
-48.27%
Downside
Reiterated
04/11/25
Barclays
$40
Hold
-17.24%
Downside
Downgraded
02/25/25
Best Analysts Covering Hims & Hers Health
1 Month
xxx
Success Rate
12/21 ratings generated profit
Average Return
+0.65%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 1 Month would result in 57.14% of your transactions generating a profit, with an average return of +0.65% per trade.
3 Months
xxx
Success Rate
14/21 ratings generated profit
Average Return
-2.04%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 3 Months would result in 66.67% of your transactions generating a profit, with an average return of -2.04% per trade.
1 Year
Success Rate
15/21 ratings generated profit
Average Return
+13.87%
reiterated a sell rating 9 days ago
Copying Allen Lutz's trades and holding each position for 1 Year would result in 71.43% of your transactions generating a profit, with an average return of +13.87% per trade.
2 Years
xxx
Success Rate
15/21 ratings generated profit
Average Return
+20.48%
reiterated a xxx
rating 9 days ago
Copying xxxxxxxxxxxxxxxxxx
trades and holding each position for 2 Years would result in 71.43% of your transactions generating a profit, with an average return of +20.48% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.
HIMS Analyst Recommendation Trends
Rating
Apr 25
May 25
Jun 25
Jul 25
Aug 25
Strong Buy
2
1
2
2
2
Buy
9
7
10
17
15
Hold
25
25
32
27
25
Sell
14
16
16
11
8
Strong Sell
2
0
1
2
2
total
52
49
61
59
52
Each month's total comprises the sum of three months' worth of ratings.
HIMS Financial Forecast
HIMS Stock Forecast FAQ
What is HIMS’s average 12-month price target, according to analysts?
Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 49.11.
What is HIMS’s upside potential, based on the analysts’ average price target?
Hims & Hers Health has 1.61% upside potential, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
How can I follow the stock ratings of top Wall Street analysts?
Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
Is HIMS a Buy, Sell or Hold?
Hims & Hers Health has a consensus rating of Hold which is based on 2 buy ratings, 7 hold ratings and 2 sell ratings.
What is Hims & Hers Health’s price target?
The average price target for Hims & Hers Health is 49.11. This is based on 11 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $85.00 ,the lowest forecast is $28.00. The average price target represents 1.61% Increase from the current price of $48.33.
The highest analyst price target is $85.00 ,the lowest forecast is $28.00. The average price target represents 1.61% Increase from the current price of $48.33.
What do analysts say about Hims & Hers Health?
Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 11 Wall Streets Analysts.
How can I buy shares of HIMS?
Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.